The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages

  Verbeek, Hans H G ^a   Alves, Maria M ^a   De Groot, Jan Willem B ^a   Osinga, Jan ^a   Plukker, John T M ^a   Links, Thera P ^a   Hofstra, Robert M W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VANDETANIB; XL 184;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MEN2A GENE; MEN2B GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RET GENE; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

ANILIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; PYRROLES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID GLAND; TUMOR CELLS, CULTURED;

EID: 79956290905     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2381     Document Type: Article

References (20)

1. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27:535-560 (Pubitemid 44213230)
2. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G, Lips CJ, Buys CH 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
3. Eng C, Mulligan LM 1997 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9:97-109 (Pubitemid 27133173)
4. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031-1037 (Pubitemid 32267972)
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 (Pubitemid 34879334)
8. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA 2005 Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866-873 (Pubitemid 46224187)
9. Ye L, Santarpia L, Gagel RF 2010 The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578-599
10. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469 (Pubitemid 47435321)
11. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F 2007 Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157:215-220 (Pubitemid 47233127)
12. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely Jr PE, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2830
13. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
14. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323 (Pubitemid 351415790)
15. Wells Jr SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772
16. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671
17. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
18. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE, Phase 2 study of sunitinib in refractory thyroid cancer. Proc 44th Annual ASCO Meeting, Chicago, May 30-June 3, 2008 (Abstract 6025)
19. Kurzrock R, Cohen EE, Sherman SI, Pfister DG, Cohen RB, Ball D, Hong DS, Ng CS, Salgia R, Ratain MJ, Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Proc 46th Annual ASCO Meeting, Chicago, June 4-8, 2010 (Abstract 5502)
20. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM 2007 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282:29230-29240 (Pubitemid 350043334)